Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Phytelligence was an agricultural biotechnology company that specialized in a proprietary non-soil-based micropropagation process called MultiPHY. Spun out of Washington State University, the company provided fruit tree growers with genetically confirmed, virus-free plants that grew significantly faster and had higher survival rates than traditional nursery trees. Their technology aimed to reduce the time required to bring new fruit varieties to market by bypassing traditional soil-based nursery cycles. The company's platform allowed for the rapid scaling of high-demand cultivars like apples, cherries, and grapes. However, following a high-profile legal dispute with Washington State University over the rights to the Cosmic Crisp apple variety, the company was declared insolvent and entered receivership in 2019. Its assets and technology licenses were subsequently acquired by NuPhY Inc. in 2020 to continue the development of the MultiPHY technology.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Phytelligence.